Search Site

Trends banner

SAIB reports $139 million Q1 net profit

its assets increased by 20.08 percent to $43.65bn.

Nissan forecasts $5.3bn annual net loss

Last year, it announced 9,000 job cuts worldwide.

Saudia to acquire 20 wide-body aircraft

10 of these being acquired for its flydaeal low-cost airline

ADIB’s Q1 net profit $517 million

Q1 2025 net profit before tax increased 18% YoY.

Emirates Islamic Q1 profit $394m

The bank's profit crossed AED 1bn mark for the first time.

GSK to buy Aiolos Bio

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK's push into its core drugmaking business. (AFP)
  • The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma
  • AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment

London, United Kingdom – British drugmaker GlaxoSmithKline on Tuesday agreed to buy Aiolos Bio for up to $1.4 billion, with focus on an asthma medication still at the testing stage.

The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma.

GSK said in a statement that the drug has the “potential to… reach a broader portion of asthma patients”.

AIO-001 was exclusively licensed to Aiolos outside of China by Jiangsu Hengrui Pharmaceuticals, which initially developed the asthma treatment.

The purchase of Aiolos Bio, based in London and San Francisco, furthers GSK’s push into its core drugmaking business after the spinoff of consumer healthcare unit Haleon in 2022.

“We have a proud heritage and deep development expertise in respiratory medicines,” GSK’s chief scientific officer Tony Wood said in the statement.

“Adding AIO-001, a potentially best-in-class medicine… could expand the reach of our current respiratory biologics portfolio.”